Find out about financial assistance for patients
For US residents only.
ZYKADIA® (ceritinib) tablets is a prescription medicine that is used to treat people with non-small cell lung cancer (NSCLC) that is caused by a defect in a gene called anaplastic lymphoma kinase (ALK) and has spread to other parts of the body.
It is not known if ZYKADIA is safe and effective in children.
Since the abnormal ALK gene is thought to play a critical role in the growth of cancer cells in ALK+ NSCLC, ZYKADIA targets this abnormal gene. As an ALK inhibitor, ZYKADIA may help to shrink or slow cancer cell growth in patients with this type of cancer. ZYKADIA may also affect healthy cells, which may lead to side effects.
ZYKADIA was studied in ALK+ metastatic NSCLC in 2 clinical trials to determine if the product was safe and effective. One trial looked at patients who were taking it as their first treatment. The other trial looked at patients who were switching to ZYKADIA after receiving a different targeted treatment.
You and your health care provider need to discuss the possible benefits and risks of treatment with ZYKADIA, taking into account your medical history and current medications.